Biotech Strategy Blog

AACR 2013 Posters offer Insights into Biotech Drug Development

Pieter Droppert — Mon, 15 Apr 2013 14:43:49 +0000

In my final post from the 2013 annual meeting of the American Association for Cancer Research (AACR), I wanted to…

Pieter Droppert — Fri, 12 Apr 2013 15:05:11 +0000

My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research…

Pieter Droppert — Thu, 11 Apr 2013 14:28:32 +0000

I will be writing in the next few days about some of the Pharma and Biotech winners and losers at…

Pieter Droppert — Mon, 08 Apr 2013 13:00:14 +0000

Genentech’s next generation PI3-kinase inhibitor, GDC-0032, was the topic of two presentations yesterday at the 2013 annual meeting of the…

Pieter Droppert — Sun, 07 Apr 2013 14:36:35 +0000

The cherry blossoms are finally blooming in Washington DC for the 2013 annual meeting of the American Association for Cancer…

Pieter Droppert — Wed, 06 Mar 2013 12:36:19 +0000

Galeterone (Tokai Pharmaceuticals) is a new prostate cancer drug in development that has an interesting triple mechanism of action in…

Pieter Droppert — Thu, 28 Feb 2013 13:22:41 +0000

The forthcoming annual meeting of the American Association for Cancer Research (AACR) in Washington DC is a must attend for…

Pieter Droppert — Fri, 15 Feb 2013 13:33:12 +0000

Following a death due to tumor lysis syndrome, AbbVie ($ABBV) have suspended the ABT-199 clinical trial program. ABT-199 is a…

Pieter Droppert — Wed, 13 Feb 2013 00:41:57 +0000

It’s disappointing to learn from the ASCO 2013 GU symposium abstracts published today that Bristol Myers Squibb’s tyrosine kinase inhibitor,…

Pieter Droppert — Fri, 01 Feb 2013 13:37:59 +0000

What’s hot in prostate cancer at the forthcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (twitter hashtag…